Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies
Efficacy of KL1333 in adult patients with primary mitochondrial disease
Full IRB Study Title:
An interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose, adaptive study of the efficacy of KL1333 in adult patients with primary mitochondrial disease
IRB Study ID: 2023-006
For complete details, please view the study on Clinicaltrials.gov
Study Sponsor:
Abliva AB
We are currently recruiting
If you are interested in this study or have questions about your child's eligibility, please contact:
Josselyn Coppenger BSN, RN / 330-543-6164
Lead Investigator
Bruce H. Cohen, MD, FAAN
Director, NeuroDevelopmental Science Center; Philip H. Maynard Chair in NeuroDevelopmental Science Fund; Chairman, American Academy of Neurology Advocacy Committee; Pediatric Neurologist
Pediatric Brain Tumor ProgramPediatric NeurologyMitochondrial Center
